Patents by Inventor William Henry Miller
William Henry Miller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11555040Abstract: The invention is directed to compounds of formula (I), and salts thereof. The compounds are inhibitors of kinase activity, in particular PI3-kinase activity.Type: GrantFiled: April 16, 2018Date of Patent: January 17, 2023Assignee: GlaxoSmithKline Intellectual Property Development LimitedInventors: Andrew Baxter, Sophie Marie Bertrand, Matthew Campbell, Kenneth David Down, Curt Dale Haffner, Julie Nicole Hamblin, Zoe Alicia Henley, William Henry Miller, Eric Philippe Andre Talbot, Jonathan Andrew Taylor
-
Publication number: 20220324875Abstract: The invention is directed to compounds of formula (I), and salts thereof. The compounds are inhibitors of kinase activity, in particular PI3-kinase activity.Type: ApplicationFiled: April 16, 2018Publication date: October 13, 2022Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITEDInventors: Andrew BAXTER, Sophie Marie BERTRAND, Matthew CAMPBELL, Kenneth David DOWN, Curt Dale HAFFNER, Julie Nicole HAMBLIN, Zoe Alicia HENLEY, William Henry MILLER, Eric Philippe Andre TALBOT, Jonathan Andrew TAYLOR
-
Patent number: 10975056Abstract: The invention is directed to substituted pyridine derivatives. Specifically, the invention is directed to compounds according to Formula (Iar): wherein Yar, X1ar, X2ar, R1ar, R2ar, R3ar, R4ar and R5ar are as defined herein; or a pharmaceutically acceptable salt or prodrug thereof. The compounds of the invention are selective inhibitors of DNMT1 and can be useful in the treatment of cancer, pre-cancerous syndromes, beta hemoglobinopathy disorders, sickle cell disease, sickle cell anemia, and beta thalassemia, and diseases associated with DNMT1 inhibition. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.Type: GrantFiled: June 13, 2017Date of Patent: April 13, 2021Assignees: GlaxoSmithKline Intellectual Property Development Limited, Cancer Research Technology Ltd.Inventors: Nicholas David Adams, Andrew B. Benowitz, María Lourdes Rueda Benede, Karen Anderson Evans, David T Fosbenner, Bryan Wayne King, Mei Li, Juan Ignacio Luengo, William Henry Miller, Alexander Joseph Reif, Stuart Paul Romeril, Stanley J. Schmidt, Roger J. Butlin, Kristin M. Goldberg, Allan M. Jordan, Christopher S. Kershaw, Ali Raoof, Bohdan Waszkowycz
-
Patent number: 10590135Abstract: The present invention relates to novel substituted bridged urea compounds, corresponding related analogs, pharmaceutical compositions and methods of use thereof. Sirtuin-modulating compounds of the present invention may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. The present invention also related to compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.Type: GrantFiled: November 19, 2015Date of Patent: March 17, 2020Assignee: GLAXOSMITHKLINE LLCInventors: Charles A. Blum, Richard Dana Caldwell, Rebecca Casaubon, Jeremy S. Disch, Ryan Michael Fox, Karsten Koppetsch, William Henry Miller, Pui Yee Ng, Christopher Oalmann, Robert B. Perni, Bruce G. Szczepankiewicz, Brian H. White
-
Publication number: 20190194166Abstract: The invention is directed to substituted pyridine derivatives. Specifically, the invention is directed to compounds according to Formula (Iar): wherein Yar, X1ar, X2ar, R1ar, R2ar, R3ar, R4ar and R5ar are as defined herein; or a pharmaceutically acceptable salt or prodrug thereof. The compounds of the invention are selective inhibitors of DNMT1 and can be useful in the treatment of cancer, pre-cancerous syndromes, beta hemoglobinopathy disorders, sickle cell disease, sickle cell anemia, and beta thalassemia, and diseases associated with DNMT1 inhibition. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.Type: ApplicationFiled: June 13, 2017Publication date: June 27, 2019Inventors: Nicholas David ADAMS, Andrew B. BENOWITZ, María Lourdes Rueda BENEDE, Karen Anderson EVANS, David T. FOSBENNER, Bryan Wayne KING, Mei LI, Juan Ignacio LUENGO, William Henry MILLER, Alexander Joseph REIF, Stuart Paul ROMERIL, Stanley J. SCHMIDT, Roger J. BUTLIN, Kristen M. GOLDBERG, Allan M. JORDAN, Christopher S. KERSHAW, Ali RAOOF, Bohdan WASZKOWYCS
-
Publication number: 20190048016Abstract: The present invention relates to novel substituted bridged urea analog compounds of Formula (I) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds, alone or in combination with other therapeutic agents, as Sirtuin Modulators useful for increasing lifespan of a cell, and in treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity.Type: ApplicationFiled: November 19, 2015Publication date: February 14, 2019Inventors: James Lamond ELLIS, Karen Anderson EVANS, Ryan Michael FOX, William Henry MILLER, Mark Andrew SEEFELD
-
Publication number: 20180319810Abstract: The present invention relates to novel substituted bridged urea analog compounds of Formula (I) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds, alone or in combination with other therapeutic agents, as Sirtuin Modulators useful for increasing lifespan of a cell, and in treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity.Type: ApplicationFiled: November 19, 2015Publication date: November 8, 2018Inventors: James Lamond ELLIS, Karen Anderson EVANS, Ryan Michaael FOX, William Henry MILLER, Mark Andrew SEEFELD
-
Patent number: 10072011Abstract: The present invention relates to novel substituted bridged urea analog compounds of Formula (I) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds, alone or in combination with other therapeutic agents, as Sirtuin Modulators useful for increasing lifespan of a cell, and in treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity.Type: GrantFiled: November 19, 2015Date of Patent: September 11, 2018Assignee: GlaxoSmithKline Intellectual Property (No. 2) LimitedInventors: James Lamond Ellis, Karen Anderson Evans, Ryan Michael Fox, William Henry Miller, Mark Andrew Seefeld
-
Publication number: 20170362234Abstract: The present invention relates to novel substituted bridged urea analog compounds of Formula (I) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds, alone or in combination with other therapeutic agents, as Sirtuin Modulators useful for increasing lifespan of a cell, and in treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity.Type: ApplicationFiled: November 19, 2015Publication date: December 21, 2017Inventors: James Lamond ELLIS, Karen Anderson EVANS, Ryan Michael FOX, William Henry MILLER, Mark Andrew SEEFELD
-
Publication number: 20170355705Abstract: The present invention relates to novel substituted bridged urea analog compounds of Formula (I) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds, alone or in combination with other therapeutic agents, as Sirtuin Modulators useful for increasing lifespan of a cell, and for use in treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity.Type: ApplicationFiled: November 19, 2015Publication date: December 14, 2017Inventors: James Lamond ELLIS, Karen Anderson EVANS, Ryan Michael FOX, William Henry MILLER, Mark Andrew SEEFELD
-
Publication number: 20170355697Abstract: The present invention relates to novel substituted bridged urea compounds, corresponding related analogs, pharmaceutical compositions and methods of use thereof. Sirtuin-modulating compounds of the present invention may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. The present invention also related to compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.Type: ApplicationFiled: November 19, 2015Publication date: December 14, 2017Inventors: Charles A. BLUM, Richard Dana CALDWELL, Rebecca CASAUBON, Jeremy S. DISCH, Ryan Michael FOX, Karsten KOPPETSCH, William Henry MILLER, Pui Yee NG, Christopher OALMANN, Robert B. PERNI, Bruce G. SZCZEPANKIEWICZ, Brian H. WHITE
-
Patent number: 9834558Abstract: The present invention relates to novel substituted bridged urea compounds of Formula (I): or a pharmaceutically acceptable salt thereof, corresponding related analogs, pharmaceutical compositions and methods of use thereof. Sirtuin-modulating compounds of the present invention may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. The present invention also related to compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.Type: GrantFiled: November 19, 2014Date of Patent: December 5, 2017Assignee: GLAXOSMITHKLINE LLCInventors: Charles A. Blum, Richard Dana Caldwell, Rebecca Casaubon, Jeremy S. Disch, Ryan Michael Fox, Karsten Koppetsch, William Henry Miller, Pui Yee Ng, Christopher Oalmann, Robert B. Perni, Bruce G. Szczepankiewicz, Brian White
-
Patent number: 9790212Abstract: This invention relates to novel compounds according to Formula (III)(a) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), and to pharmaceutical compositions containing them.Type: GrantFiled: October 13, 2016Date of Patent: October 17, 2017Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITEDInventors: Charles William Blackledge, Jr., Joelle Lorraine Burgess, Neil W. Johnson, Jiri Kasparec, Steven David Knight, Louis V. LaFrance, III, Juan I. Luengo, William Henry Miller, Kenneth Allen Newlander, Stuart Paul Romeril, Mark Schulz, Dai-Shi Su, Xinrong Tian
-
Patent number: 9649307Abstract: Herein are disclosed indoles of formula (I) where the various groups are defined herein, and which are useful for treating cancer.Type: GrantFiled: June 20, 2016Date of Patent: May 16, 2017Assignee: GlaxoSmithKline LLCInventors: William Henry Miller, Xinrong Tian, Sharad Kumar Verma
-
Publication number: 20170029412Abstract: This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.Type: ApplicationFiled: October 13, 2016Publication date: February 2, 2017Inventors: Charles William BLACKLEDGE, JR., Joelle Lorraine BURGESS, Neil W. JOHNSON, Jiri KASPAREC, Steven David KNIGHT, Louis V. LaFRANCE, III, Juan I. LUENGO, William Henry MILLER, Kenneth Allen NEWLANDER, Stuart Paul ROMERIL, Mark SCHULZ, Dai-Shi SU, Xinrong TIAN
-
Publication number: 20170015666Abstract: This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.Type: ApplicationFiled: March 6, 2015Publication date: January 19, 2017Inventors: William Henry MILLER, Stuart Paul ROMERIL, Xinrong TIAN, Sharad Kumar VERMA
-
Patent number: 9505745Abstract: This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.Type: GrantFiled: April 25, 2014Date of Patent: November 29, 2016Assignee: GlaxoSmithKline Intellectual Property (No. 2) LimitedInventors: Charles William Blackledge, Jr., Joelle Lorraine Burgess, Neil W. Johnson, Jiri Kasparec, Steven David Knight, Louis V. LaFrance, III, Juan I. Luengo, William Henry Miller, Kenneth Allen Newlander, Stuart Paul Romeril, Mark Schulz, Dai-Shi Su, Xinrong Tian
-
Publication number: 20160296518Abstract: Herein are disclosed indoles of formula (I) where the various groups are defined herein, and which are useful for treating cancer.Type: ApplicationFiled: June 20, 2016Publication date: October 13, 2016Inventors: William Henry MILLER, Xinrong TIAN, Sharad Kumar VERMA
-
Patent number: 9402836Abstract: Herein are disclosed indoles of formula (I) where the various groups are defined herein, and which are useful for treating cancer.Type: GrantFiled: July 9, 2015Date of Patent: August 2, 2016Assignee: GlaxoSmithKline LLCInventors: James Brackley, III, Joelle Lorraine Burgess, Seth Wilson Grant, Neil W. Johnson, Steven David Knight, Louis Vincent LaFrance, III, William Henry Miller, Kenneth Allen Newlander, Stuart Paul Romeril, Meagan B. Rouse, Xinrong Tian, Sharad Kumar Verma
-
Patent number: 9382234Abstract: This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.Type: GrantFiled: December 12, 2013Date of Patent: July 5, 2016Assignee: GlaxoSmithKline LLCInventors: Steven David Knight, William Henry Miller, Kenneth Allen Newlander, Carla A. Donatelli